Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM Qilian International Holding Group	$11.57 -18.9%	$11.40	$5.26 ▼ $16.50	$1.12B	1.33	26,420 shs	42,218 shs
GPCR Structure Therapeutics	$22.20 -7.0%	$21.61	$13.22 ▼ $62.74	$1.27B	-1.69	935,447 shs	819,923 shs
SPRY ARS Pharmaceuticals	$14.85 +1.6%	$13.73	$7.55 ▼ $18.51	$1.46B	0.84	1.26 million shs	960,806 shs
VIGL Vigil Neuroscience	$7.89 +0.1%	$2.43	$1.31 ▼ $7.95	$368.24M	1.9	649,716 shs	1.95 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM Qilian International Holding Group	+1.81%	+20.75%	+32.02%	+51.14%	+1,492,499,900.00%
GPCR Structure Therapeutics	-2.81%	-3.28%	+0.51%	+20.43%	-35.62%
SPRY ARS Pharmaceuticals	-2.40%	+2.02%	+6.17%	+42.91%	+62.81%
VIGL Vigil Neuroscience	-0.13%	+217.74%	+340.22%	+195.13%	+117.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	2.2583 of 5 stars	3.5	1.0	0.0	0.0	3.6	1.7	0.6
SPRY ARS Pharmaceuticals	2.4143 of 5 stars	3.6	0.0	0.0	0.0	2.4	4.2	0.6
VIGL Vigil Neuroscience	3.1231 of 5 stars	4.0	3.0	0.0	0.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM Qilian International Holding Group	0.00	N/A	N/A	N/A
GPCR Structure Therapeutics	3.00	Buy	$79.86	259.72% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	108.75% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	36.88% Upside

Current Analyst Ratings Breakdown

Latest VIGL, SPRY, BGM, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/22/2025	VIGL Vigil Neuroscience	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$13.00 ➝ $8.00
5/12/2025	GPCR Structure Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $75.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM Qilian International Holding Group	$25.10M	44.82	N/A	N/A	$6.10 per share	1.90
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$9.77 per share	N/A
SPRY ARS Pharmaceuticals	$97.12M	15.02	N/A	N/A	$2.40 per share	6.19
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$3.24 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM Qilian International Holding Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	-$89.62M	-$0.87	N/A	N/A	N/A	N/A	-16.37%	-15.68%	8/14/2025 (Estimated)
SPRY ARS Pharmaceuticals	-$54.37M	-$0.16	N/A	N/A	N/A	N/A	-22.56%	-21.82%	8/5/2025 (Estimated)
VIGL Vigil Neuroscience	-$82.64M	-$2.05	N/A	N/A	N/A	N/A	-83.89%	-65.34%	8/12/2025 (Estimated)

Latest VIGL, SPRY, BGM, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
3/20/2025	Q4 2024	SPRY ARS Pharmaceuticals	-$0.04	$0.52	+$0.56	$0.52	$15.46 million	$86.58 million
3/13/2025	Q4 2024	VIGL Vigil Neuroscience	-$0.49	-$0.57	-$0.08	-$0.57	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM Qilian International Holding Group	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM Qilian International Holding Group	N/A	3.39	2.82
GPCR Structure Therapeutics	N/A	27.63	27.63
SPRY ARS Pharmaceuticals	N/A	12.56	12.52
VIGL Vigil Neuroscience	N/A	3.72	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM Qilian International Holding Group	N/A
GPCR Structure Therapeutics	91.78%
SPRY ARS Pharmaceuticals	68.16%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
BGM Qilian International Holding Group	58.66%
GPCR Structure Therapeutics	9.43%
SPRY ARS Pharmaceuticals	33.50%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM Qilian International Holding Group	298	97.22 million	2.48 million	N/A
GPCR Structure Therapeutics	136	57.34 million	51.86 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	58.21 million	Optionable
VIGL Vigil Neuroscience	40	46.67 million	27.38 million	Not Optionable

VIGL, SPRY, BGM, and GPCR Headlines

Recent News About These Companies

HC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 28 at 11:51 AM | marketbeat.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28 at 6:35 AM | msn.com

Woodline Partners LP Has $831,000 Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 28 at 4:30 AM | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Average Target Price from Brokerages

May 28 at 2:55 AM | americanbankingnews.com

Wedbush Equities Analysts Reduce Earnings Estimates for VIGL

May 27 at 2:22 AM | marketbeat.com

Q2 EPS Estimate for Vigil Neuroscience Boosted by Analyst

May 27 at 1:25 AM | americanbankingnews.com

William Blair Issues Optimistic Outlook for VIGL Earnings

May 27 at 1:18 AM | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Mizuho

May 26 at 7:13 AM | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Stock Rating Lowered by Guggenheim

May 26 at 7:13 AM | marketbeat.com

Point72 Asset Management L.P. Cuts Stock Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

May 26 at 4:06 AM | marketbeat.com

Mizuho Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

May 26 at 1:59 AM | americanbankingnews.com

Equities Analysts Issue Forecasts for VIGL FY2027 Earnings

May 25 at 8:42 AM | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to Hold at Citizens Jmp

May 25 at 7:35 AM | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Recommendation of "Hold" from Analysts

May 25 at 5:09 AM | marketbeat.com

Vigil Neuroscience (NASDAQ:VIGL) Given Market Perform Rating at JMP Securities

May 25 at 4:11 AM | americanbankingnews.com

Vigil Neuroscience (NASDAQ:VIGL) Cut to "Hold" at Wedbush

May 25 at 1:51 AM | americanbankingnews.com

Vigil Neuroscience Analyst Ratings and Price Targets | NASDAQ:VIGL | Benzinga

May 24, 2025 | benzinga.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil ...

May 24, 2025 | morningstar.com

JMP Securities Reaffirms Market Perform Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 24, 2025 | marketbeat.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

May 24, 2025 | financialpost.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

May 24, 2025 | financialpost.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIGL, SPRY, BGM, and GPCR Company Descriptions

Qilian International Holding Group NASDAQ:BGM

$11.57 -2.70 (-18.92%)

Closing price 03:59 PM Eastern

Extended Trading

$11.80 +0.23 (+1.99%)

As of 07:56 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Structure Therapeutics NASDAQ:GPCR

$22.20 -1.66 (-6.96%)

Closing price 04:00 PM Eastern

Extended Trading

$22.60 +0.40 (+1.78%)

As of 07:53 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

ARS Pharmaceuticals NASDAQ:SPRY

$14.85 +0.23 (+1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$15.18 +0.33 (+2.19%)

As of 07:38 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Vigil Neuroscience NASDAQ:VIGL

$7.89 +0.01 (+0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$7.88 -0.01 (-0.19%)

As of 06:35 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time